By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today announced revenues of $345,000 for the fourth quarter and $1.2 million for full-year 2010, the first year that its OVA1 triage test for ovarian cancer was commercially available.

For the three months ended Dec. 31, 2010, the Austin, Texas-based molecular diagnostics company posted revenues of $345,000, compared to no revenues a year ago. Wall Street had expected $660,000 for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.